Does Molina Healthcare Cover Prolia?

What Is Prolia and Why Is It Prescribed?

Prolia (denosumab) is a fully human monoclonal antibody that inhibits RANK ligand (RANKL), the key cytokine that stimulates osteoclast-mediated bone resorption. The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later extended approval to men with osteoporosis, patients on glucocorticoid therapy, and patients with bone loss from androgen-deprivation therapy or aromatase-inhibitor therapy [1].

Mechanism and Dosing

The standard dose is 60 mg administered as a single subcutaneous injection once every 6 months by a healthcare professional. Unlike oral bisphosphonates, denosumab does not require fasting, renal dose adjustment (for most patients), or special swallowing instructions. The FDA label specifies that patients should also receive calcium 1,000 mg daily and at least 400 IU vitamin D daily during treatment [1].

Clinical Efficacy Evidence

The FREEDOM trial (N=7,868 postmenopausal women with osteoporosis, T-score between negative 2.5 and negative 4.0 at the lumbar spine or total hip) showed denosumab reduced new vertebral fractures by 68% (7.2% placebo vs. 2.3% denosumab, P<0.001) and hip fractures by 40% (1.2% vs. 0.7%, P=0.04) over 36 months compared with placebo [2]. The FREEDOM Extension study followed participants for up to 10 years and demonstrated sustained bone mineral density (BMD) gains without plateau [3].

For glucocorticoid-induced osteoporosis, a 12-month randomized controlled trial (N=795) published in the New England Journal of Medicine found denosumab produced significantly greater increases in lumbar spine BMD than risedronate (4.4% vs. 2.3%, P<0.001) [4].

These data inform why national guidelines prioritize denosumab as a second-line or high-risk first-line agent. The 2020 American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) clinical practice guidelines for postmenopausal osteoporosis state: "Denosumab is appropriate as initial therapy in patients with high fracture risk, renal impairment, or intolerance to oral agents" [5].

How Molina Healthcare Structures Its Drug Coverage

Molina Healthcare operates Medicaid managed care, Medicare Advantage, and Marketplace plans across more than 20 states. Because Medicaid is administered state by state, coverage policies for specialty drugs like Prolia are not uniform across Molina's footprint.

Formulary Tiers and Medical vs. Pharmacy Benefit

Prolia can be covered under either the pharmacy benefit (as a specialty-tier medication dispensed through a specialty pharmacy) or the medical benefit (as a provider-administered drug billed under a J-code, specifically J0897, at the point of care). Which benefit applies depends on the Molina state contract and the setting of care.

When covered under the pharmacy benefit, Prolia typically lands on Tier 4 or Tier 5 (specialty tier), which carries the highest cost-sharing. Under the medical benefit at a physician's office or infusion center, cost-sharing is calculated differently and is often lower for Medicaid members.

Prior Authorization Requirements

Prior authorization (PA) is required for Prolia under virtually all Molina state plans. The PA submission typically must include:

• A current DXA scan report showing a T-score at or below negative 2.5, or a T-score between negative 1.0 and negative 2.5 with a 10-year FRAX hip fracture probability at or above 3% or major osteoporotic fracture probability at or above 20% [5]
• Documentation of at least one fragility fracture, or two or more clinical risk factors for fracture
• A 6-month or longer trial of a bisphosphonate (most commonly alendronate 70 mg weekly or risedronate 35 mg weekly), unless a documented contraindication or intolerance exists
• Prescriber attestation that Prolia is medically necessary

Step Therapy: The Bisphosphonate-First Rule

Molina, like most Medicaid managed care plans, applies step therapy for osteoporosis medications. Bisphosphonates are generically available and represent the first-line recommendation in multiple guidelines, including the 2022 USPSTF recommendation statement on osteoporosis screening [6] and the 2020 AACE/ACE guidelines [5]. Molina's step therapy protocol generally requires:

1. A documented trial of alendronate or risedronate for at least 6 months
2. Evidence of inadequate response (continued BMD decline or incident fracture), intolerance (esophageal adverse effects, inability to remain upright 30 minutes), or a clinical contraindication (creatinine clearance below 35 mL/min for most bisphosphonates)

If any of these conditions are met and documented in the PA request, Molina's clinical pharmacists reviewing the case are more likely to approve Prolia on the first submission.

Step-by-Step: Getting Prolia Approved Through Molina

Getting PA approved on the first attempt saves weeks of delay and prevents a gap in therapy, which is clinically meaningful given that discontinuing denosumab without transitioning to a bisphosphonate carries a documented rebound fracture risk [7].

Step 1: Confirm Your Specific Plan's Formulary

Call the member services number on the back of your Molina ID card and ask specifically:

• Is Prolia (denosumab 60 mg) covered on my formulary?
• Is it covered under my pharmacy benefit or medical benefit?
• What are the prior authorization criteria?

You can also search Molina's online formulary tool at molina healthcare's website by entering your state, plan type, and plan year.

Step 2: Have Your Prescriber Submit a Complete PA Package

Incomplete PA submissions are the leading reason for initial denials. Your prescriber's office should include all of the following in a single submission:

• DXA report with T-scores at the lumbar spine, femoral neck, and total hip
• FRAX calculation printout
• A list of all prior osteoporosis medications with start dates, stop dates, and reason for discontinuation
• Most recent renal function panel (eGFR) if bisphosphonate contraindication is being claimed
• Any radiology or surgical reports confirming fractures
• A completed Molina PA form (available on the Molina provider portal) or a CMS-standard prior authorization request form

Step 3: Request a Peer-to-Peer Review if Initially Denied

If the PA is denied, the prescriber has the right to request a peer-to-peer (P2P) review with Molina's medical director within the denial appeal window, typically within 14 days of denial notification. During the P2P call, the prescriber can present clinical context not captured in written documentation. Studies on PA processes in Medicaid show that peer-to-peer review reverses approximately 27% to 50% of initial specialty drug denials [8].

Step 4: File a Formal Appeal

If the P2P review does not result in approval, file a formal first-level appeal. Attach a written letter of medical necessity from the prescriber citing the FREEDOM trial data [2], the AACE/ACE guidelines [5], and any patient-specific fracture risk data. Most state Medicaid rules require Molina to respond to standard appeals within 30 days and expedited appeals within 72 hours when a delay would seriously jeopardize health.

What Happens If Prolia Is Denied?

A denial is not the end of the road. Several parallel strategies can run alongside the formal appeal process.

Manufacturer Patient Support: Amgen Prolia NEXT STEP

Amgen operates the Prolia NEXT STEP support program, which offers free drug through the Amgen Safety Net Foundation for patients who meet income eligibility criteria (generally household income at or below 500% of the federal poverty level) and who do not have adequate insurance coverage. Patients can call 1-800-772-6436 or visit amgensupportive.com to apply. Approval can come within days for patients facing acute fracture risk.

State Medicaid External Review

All 50 states have processes for external independent review of Medicaid managed care denials. The external reviewer is a clinical organization independent of Molina, and their decision is binding. Filing for external review simultaneously with your Molina internal appeal is allowed in most states and recommended when fracture risk is high.

Alternative Covered Agents While Appealing

If a gap in treatment while the appeal proceeds is clinically unacceptable, the prescriber may transition the patient to a covered agent temporarily. Zoledronic acid (zoledronate 5 mg IV once yearly) is often covered under Molina's medical benefit and has strong fracture-reduction evidence from the HORIZON Key Fracture Trial (N=7,765, 70% reduction in vertebral fractures, P<0.001) [9]. For patients who have already been on denosumab and are facing a coverage lapse, transitioning to zoledronic acid is specifically recommended by expert consensus to prevent rebound vertebral fractures [7].

Clinical Context: Who Is Most Likely to Get Prolia Approved on First Submission?

Not every Molina member requesting Prolia faces the same hurdle. The following clinical profiles align most closely with Molina's published and common-practice PA criteria, based on available guideline documents and typical Medicaid formulary standards [5][6].

High-Fracture-Risk Profile

Patients with the strongest case for first-submission approval typically have at least two of the following:

• T-score at or below negative 2.5 at the lumbar spine or hip on DXA
• A prior fragility fracture (vertebral, hip, wrist, or proximal humerus)
• FRAX 10-year probability for major osteoporotic fracture at or above 20%
• Age 70 or older with additional clinical risk factors (low body weight, smoking, glucocorticoid use)

A 2019 analysis in the Journal of Bone and Mineral Research found that patients with a prior vertebral fracture have a 5-fold higher risk of subsequent vertebral fracture within 1 to 2 years, an observation that strengthens the medical necessity argument for immediate denosumab therapy rather than step therapy through bisphosphonates [10].

Patients With Bisphosphonate Contraindications

Renal impairment is the clearest bisphosphonate contraindication. Alendronate is contraindicated when creatinine clearance falls below 35 mL/min. Denosumab has no renal dose adjustment requirement and can be used in patients with advanced chronic kidney disease, though hypocalcemia risk requires careful monitoring in this population. The FDA label explicitly notes that no dose adjustment is needed for renal impairment [1]. This clinical reality makes denosumab the logical first-line agent for patients with CKD stage 3b or higher and documented osteoporosis.

Documented esophageal disease (Barrett's esophagus, achalasia, strictures), inability to sit or stand upright for 30 minutes after dosing, and prior osteonecrosis of the jaw from bisphosphonate therapy also constitute valid contraindications that PA reviewers will accept.

Patients on Long-Term Glucocorticoids

Patients receiving 7.5 mg or more of prednisone (or equivalent) daily for 3 or more months have glucocorticoid-induced osteoporosis risk sufficient to warrant treatment per the 2017 American College of Rheumatology guidelines on glucocorticoid-induced osteoporosis [11]. Those at high fracture risk (T-score at or below negative 2.5 or prior fracture) may qualify for denosumab as a first-line agent under these guidelines, and that guideline citation can be included in the PA submission to support approval outside of standard step therapy.

Understanding Rebound Fracture Risk: Why Continuity of Coverage Matters

One clinical reality that distinguishes Prolia from other osteoporosis medications is the rebound vertebral fracture risk after discontinuation. When denosumab is stopped without transitioning to a bisphosphonate, bone turnover markers rebound to above-baseline levels within 3 to 6 months, and BMD returns toward pre-treatment values within 12 to 18 months. More concerning, multiple vertebral fractures have been reported in patients who discontinued denosumab without bridging therapy [7].

A 2017 case series and subsequent analyses published in Osteoporosis International identified patients with no prior vertebral fracture history who developed multiple new vertebral fractures within 7 to 18 months of denosumab discontinuation [7]. This rebound phenomenon is now widely recognized in the field and was addressed in a 2021 Endocrine Society Clinical Practice Guideline on osteoporosis, which states: "After discontinuing denosumab, sequential therapy with a bisphosphonate is recommended to prevent rapid bone loss and multiple vertebral fractures" [12].

This clinical concern strengthens the argument for uninterrupted Prolia coverage. In a Molina appeals letter, prescribers should reference this rebound fracture risk explicitly, citing the Endocrine Society guideline [12] and noting that a coverage gap itself creates a clinically dangerous situation that increases the probability of costly acute fracture care.

Prolia vs. Other Covered Osteoporosis Drugs on Molina's Formulary

Understanding where Prolia sits relative to other covered agents helps frame the medical necessity argument.

Bisphosphonates (First-Line, Generally Covered Without PA)

Generic alendronate 70 mg weekly, risedronate 35 mg weekly, and ibandronate 150 mg monthly are almost universally covered without prior authorization on Molina formularies. Zoledronic acid 5 mg IV annually is typically covered under the medical benefit with PA. Alendronate reduces vertebral fracture risk by approximately 47% to 49% in women with prior vertebral fractures in the FIT trial (N=2,027) [13].

Teriparatide and Abaloparatide (Anabolic Agents, Highest PA Hurdle)

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents with even more restrictive PA criteria than denosumab on most Molina plans. They are typically reserved for patients with T-score below negative 3.0, multiple prior fractures, or failure of two prior antiresorptive agents. They represent a higher bar, not a lower one, compared to Prolia.

Romosozumab (Evenity, Highest-Risk Patients Only)

Romosozumab 210 mg SC monthly for 12 months is FDA-approved for women with severe osteoporosis at high fracture risk [14], but it carries a boxed warning for cardiovascular events. Molina coverage criteria for romosozumab are the most restrictive of all osteoporosis agents, and it is rarely the first specialty drug approved for a new Molina member.

This context means denosumab sits at a reasonable middle point in the specialty osteoporosis formulary: more restricted than bisphosphonates but more accessible than anabolic agents or romosozumab.

Key Numbers to Put in a Prior Authorization Letter

Prescribers who cite specific clinical data in PA letters have better approval rates than those who submit generic medical necessity statements. The following data points are worth including:

• FREEDOM trial: 68% relative risk reduction in vertebral fractures over 36 months (P<0.001) [2]
• FREEDOM Extension: Sustained BMD increases at 10 years with no plateau [3]
• Glucocorticoid-induced osteoporosis RCT: 4.4% lumbar spine BMD gain with denosumab vs. 2.3% with risedronate at 12 months (P<0.001) [4]
• Rebound fracture risk: Multiple vertebral fractures reported within 7 to 18 months of denosumab discontinuation without bisphosphonate bridge [7]
• AACE/ACE 2020 guideline: Denosumab appropriate as initial therapy in patients with high fracture risk, renal impairment, or intolerance to oral agents [5]
• Endocrine Society 2021 guideline: Sequential bisphosphonate therapy recommended after denosumab to prevent rebound fractures [12]

Including these specific citations transforms a PA letter from a generic request into a document that is difficult for a plan's medical director to deny without producing contradictory clinical reasoning.